CBD Life Sciences Business Summary

CBD Life Sciences Inc. (CBDL), operating primarily through its flagship subsidiary The CBD Vault Inc., utilizes a multi-channel revenue model centered on the development and distribution of hemp-derived cannabidiol (CBD) and functional mushroom wellness products. The company generates revenue through direct-to-consumer e-commerce via its proprietary platform, Walmart Marketplace, and Groupon, supplemented by wholesale distribution to licensed dispensaries and strategic retail partnerships with luxury spas and high-traffic travel hubs like JFK International Airport. Its primary business segments encompass therapeutic topicals, ingestibles (including mushroom-infused chocolates and gummies), functional beverages, and a specialized line of pet and equine wellness solutions. CBDL competes directly with players such as cbdMD, Inc. (YCBD), ProPhase Labs, Inc. (PRPH), and Avenue Therapeutics, Inc. (ATXI), positioning itself as a high-growth micro-cap innovator that bridges the gap between the cannabis sector and mainstream consumer packaged goods through aggressive retail expansion. The leadership team is headed by President and CEO Lisa Nelson, an entrepreneur with over 25 years of executive management experience in the healthcare, hospitality, and retail industries; she also serves as the company's CFO and Treasurer. Supporting the executive suite are Brianna Nelson, who serves as Managing Director and Chief Product Developer with a focus on social media marketing and formulation, and Matthew McGee, the Chief Marketing Officer (CMO), who holds a degree in Cannabis Biology & Chemistry. The company’s strategic direction is further guided by an advisory board featuring members such as Susan Lehrer, Mark Beesley, and Mark Anderson. Despite a lean internal staff, the team leverages deep industry-specific technical knowledge and a rebranding strategy—transitioning from LBC Bioscience to The CBD Vault—to scale its footprint across the evolving $200 billion global wellness market.